Spectrum Pharmaceuticals, Inc.

NASDAQ:SPPI   1:58:22 PM EDT
0.43
-0.02 (-3.89%)
Products, Regulatory, Earnings Announcements

Spectrum Pharmaceuticals Receives Complete Response Letter From U.S. Food And Drug Administration For Poziotinib

Published: 11/25/2022 11:10 GMT
Spectrum Pharmaceuticals, Inc. (SPPI) - Spectrum Pharmaceuticals Receives Complete Response Letter From U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of Rolvedon™ (eflapegrastim-xnst) Injection.
Spectrum Pharmaceuticals Inc - to Explore Strategic Alternatives for Poziotinib Program, Including Partnerships and Business Development Opportunities.
Spectrum Pharmaceuticals-immediately De-prioritizes Poziotinib Program, Accelerates Cost Reductions, Including 75% Reduction in Research and Development Related Workforce.
Spectrum Pharmaceuticals Inc - FDA Issued a Crl Indicating Poziotinib Application Cannot Be Approved in Its Present Form.
Spectrum Pharmaceuticals Inc - Based on Crl, Co Would Have to Generate Additional Data Including a Randomized Controlled Study Prior to Approval.
Spectrum Pharmaceuticals Inc - Will Focus Efforts on Driving Growth for Recently Launched Commercial Drug, Rolvedon.
Spectrum Pharmaceuticals Inc - Believes It Will Be Able to Generate Working Capital Required to Support Its Strategic Refocusing Through 2024.
Revenue is expected to be $3.83 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $6.36 Million
Next Quarter EPS Guidance is expected to be -$0.07

More details on our Analysts Page.